Impinj, Inc. (NASDAQ:PI) recorded a trading volume of 0.55 million shares, below its 90-day volume average of 0.67 million shares. The stock kicked off the session at $25.27 and later approached $24.56 with a change of -3.57%.Impinj, Inc. (PI) Analyst Opinion
Impinj, Inc. has a consensus outperform rating from 7 Wall Street analysts, and the number of shares currently sold short amount to at least 36.04% of shares outstanding. The stock sank -25.12% last month and is down -30.5 this year. Wall Street is only getting more bullish on the stock, with 4 of analysts who cover PI having a buy-equivalent rating. Analysts have placed a $34.75 price target on Impinj, Inc., suggesting a 41.49% gain from recent close. It’s currently trading about -59.64% below its 52-week high.Impinj, Inc. Earnings Surprise
Impinj, Inc. (PI) failed to surprise the stock market in its last reported earnings when it earned -$0.08 a piece versus the consensus-estimated -$0.03. Its revenue totaled $32.58 million down -4.49% from the previous quarter.Impinj, Inc. (NASDAQ:PI) Intraday View
This stock (PI) is ahead of its 52-week low with 22.98%. Its last month’s stock price volatility remained 5.06% which for the week stands at 6.63%. The share price has moved backward from its 20 days moving average, trading at a distance of -2.41% and stays -24.21% away from its 50 days moving average. Over the last five days, shares have faced -6.51% losses and now is down -34.87% since hitting its 200-day moving average of $40.06. Impinj, Inc. (PI) has made its way to a 12-month decline of -11.37%.
Turning to Juno Therapeutics, Inc. (NASDAQ:JUNO), its shares were trading at $56.7 a gain of $2.08, on the trading floor. The stock, after opening at $54.62, touched a high of $57.25 before paring much of its gains. So far, analysts are sticking with their bullish recommendations with the consensus call at 1.9. Juno Therapeutics, Inc. has 5 buy ratings, 4 holds and 0 sells even after the stock tumbled -10.64% from its high of $63.45 to a $6.21 billion market value through last close.Juno Therapeutics, Inc. (JUNO) Consensus Price Target
The company’s consensus rating on Reuter’s scale slipped from 2 to 1.93 during a month. Analysts set a 12-month price target of $55.54 a share. The target implies a -2.05% decrease from where the shares are currently trading. Also, the current price highlights a discount of 14.64% to analysts’ high consensus price target.Juno Therapeutics, Inc. (NASDAQ:JUNO) Intraday Trading
The counter witnessed a trading volume of 1.81 million shares versus an average volume of 2.46 million shares during last trading session. Its last month’s stock price volatility remained 6.33% which for the week approaches 6.08%. The lowest price the stock reached in the last trading day was $53.5 and compares with the $17.52 52-week low. The stock recovered 223.63% since its low point and has performed 200.8% year-to-date.